S&P 500   3,220.49 (+0.72%)
DOW   26,827.34 (+0.69%)
QQQ   259.89 (-0.18%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,220.49 (+0.72%)
DOW   26,827.34 (+0.69%)
QQQ   259.89 (-0.18%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,220.49 (+0.72%)
DOW   26,827.34 (+0.69%)
QQQ   259.89 (-0.18%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,220.49 (+0.72%)
DOW   26,827.34 (+0.69%)
QQQ   259.89 (-0.18%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
Log in

NASDAQ:KNSAKiniksa Pharmaceuticals Stock Price, Forecast & News

$22.42
+0.43 (+1.96 %)
(As of 07/15/2020 01:18 PM ET)
Add
Compare
Today's Range
$21.80
Now: $22.42
$22.60
50-Day Range
$20.64
MA: $22.80
$26.00
52-Week Range
$5.01
Now: $22.42
$28.67
Volume81,884 shs
Average Volume285,440 shs
Market Capitalization$1.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.01
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor; and KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Read More
Kiniksa Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KNSA
CUSIPN/A
CIKN/A
Phone44-80-8189-6257

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.10 per share

Profitability

Net Income$-161,870,000.00

Miscellaneous

Employees111
Market Cap$1.34 billion
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive KNSA News and Ratings via Email

Sign-up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions

How has Kiniksa Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KNSA stock has increased by 37.5% and is now trading at $22.13. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kiniksa Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kiniksa Pharmaceuticals.

When is Kiniksa Pharmaceuticals' next earnings date?

Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Kiniksa Pharmaceuticals.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) announced its earnings results on Tuesday, April, 28th. The company reported ($0.48) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.15. View Kiniksa Pharmaceuticals' earnings history.

What price target have analysts set for KNSA?

6 brokerages have issued 1-year price objectives for Kiniksa Pharmaceuticals' stock. Their forecasts range from $24.00 to $40.00. On average, they expect Kiniksa Pharmaceuticals' stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 46.9% from the stock's current price. View analysts' price targets for Kiniksa Pharmaceuticals.

Has Kiniksa Pharmaceuticals been receiving favorable news coverage?

Press coverage about KNSA stock has been trending extremely negative on Wednesday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kiniksa Pharmaceuticals earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days. View the latest news about Kiniksa Pharmaceuticals.

Who are some of Kiniksa Pharmaceuticals' key competitors?

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Crispr Therapeutics (CRSP), Exelixis (EXEL), AbbVie (ABBV), Gilead Sciences (GILD), VBI Vaccines (VBIV), Vanda Pharmaceuticals (VNDA), Agile Therapeutics (AGRX), Clovis Oncology (CLVS), Dicerna Pharmaceuticals (DRNA) and ImmunoGen (IMGN).

Who are Kiniksa Pharmaceuticals' key executives?

Kiniksa Pharmaceuticals' management team includes the following people:
  • Mr. Sanj K. Patel, CEO & Chairman (Age 49)
  • Mr. Stephen Mahoney, Pres & COO (Age 47)
  • Dr. John F. Paolini, Chief Medical Officer (Age 53)
  • Mr. Chris Heberlig, Exec. VP & CFO (Age 43)
  • Mark Ragosa C.F.A., VP of Investor Relations

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Exane Derivatives (0.01%). Company insiders that own Kiniksa Pharmaceuticals stock include John F Paolini, Sanj K Patel and Thomas W Beetham. View institutional ownership trends for Kiniksa Pharmaceuticals.

Which major investors are selling Kiniksa Pharmaceuticals stock?

KNSA stock was sold by a variety of institutional investors in the last quarter, including Exane Derivatives. Company insiders that have sold Kiniksa Pharmaceuticals company stock in the last year include John F Paolini, Sanj K Patel, and Thomas W Beetham. View insider buying and selling activity for Kiniksa Pharmaceuticals.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $22.13.

How big of a company is Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals has a market capitalization of $1.32 billion. The company earns $-161,870,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Kiniksa Pharmaceuticals employs 111 workers across the globe.

What is Kiniksa Pharmaceuticals' official website?

The official website for Kiniksa Pharmaceuticals is www.kiniksa.com.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 44-80-8189-6257 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.